🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,257 results for “First” Clear

  1. fulzerasib

    The First People's Hospital of Lianyungang

    Resectable NSCLC

    phase 2 small molecule active

    1 trial

  2. gemcitabine and oxaliplatin.

    The First People's Hospital of Lianyungang

    Gallbladder Carcinoma

    phase 2 small molecule active

    1 trial

  3. golidocitinib

    The First People's Hospital of Lianyungang

    IrAE

    phase 2 small molecule active

    1 trial

  4. induction chemotherapy and immunotherapy

    The First People's Hospital of Lianyungang

    ESCC

    phase 2 small molecule completed

    1 trial

  5. intravenous infusion (IV) of Adebrelimab (ADE)

    The First People's Hospital of Lianyungang

    Advanced Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  6. lenalidomide combined with rituximab

    The First People's Hospital of Lianyungang

    Diffuse Large B Cell Lymphoma

    phase 2 small molecule active

    1 trial

  7. mFOLFOXIRI

    The First People's Hospital of Lianyungang

    Locally Advanced Rectal Cancer

    phase 2 small molecule active

    1 trial

  8. megestrol acetate oral suspension + serplulimab + SOX

    The First People's Hospital of Lianyungang

    Stage III Gastric Cancer

    phase 2 small molecule active

    1 trial

  9. mitoxantrone hydrochloride liposome

    The First People's Hospital of Lianyungang

    Relapsed/Refractory Acute Myeloid Leukaemia

    phase 2 small molecule active

    2 trials

  10. nanoparticle albumin-bound paclitaxel/carboplatin

    The First People's Hospital of Lianyungang

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  11. ondansetron

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma (HCC)

    phase 2 small molecule active

    1 trial

  12. online adaptive radiotherapy

    The First People's Hospital of Lianyungang

    Cervical Cancer

    phase 2 other active

    1 trial

  13. orelabrutinib combined with rituximab regimen

    The First People's Hospital of Lianyungang

    Marginal Zone Lymphoma(MZL)

    phase 2 small molecule active

    1 trial

  14. osimertinib mesylate tablets and anlotinib hydrochloride capsules

    The First People's Hospital of Lianyungang

    Non Small Cell Lung Cancer

    phase 2 small molecule terminated

    1 trial

  15. pembrolizumab

    The First People's Hospital of Lianyungang

    Advanced Non-squamous Non-small-cell Lung Cancer

    phase 2 small molecule active

    1 trial

  16. penpulimab, lenalidomide, Rituximab, Gemcitabine, Oxaliplatin

    The First People's Hospital of Lianyungang

    Lymphoma, Large B-Cell, Diffuse

    phase 2 small molecule active

    1 trial

  17. pharmorubicin or pirarubicin

    The First People's Hospital of Lianyungang

    Upper Tract Urothelial Carcinoma

    phase 2 small molecule active

    1 trial

  18. placebo

    The First People's Hospital of Lianyungang

    COVID-19 Thalidomide

    phase 2 small molecule active

    1 trial

  19. pyrotinib and trastuzumab in combinition with neoadjuvant chemotherapy

    The First People's Hospital of Lianyungang

    HER2-positive Breast Cancer

    phase 2 small molecule active

    1 trial

  20. recombinant humanized anti-CD25 monoclonal antibody

    The First People's Hospital of Lianyungang

    Transfusion Dependent Thalassemia

    phase 2 small molecule active

    1 trial

  21. retinal pigment epithelium transplantation

    The First People's Hospital of Lianyungang

    Dry Age-related Macular Degeneration

    phase 2 mab active

    1 trial

  22. rituximab /Dexamethasone/cyclophosphamide

    The First People's Hospital of Lianyungang

    Treatment

    phase 2 small molecule active

    1 trial

  23. sintilimab

    The First People's Hospital of Lianyungang

    Nasopharyngeal Carcinoma

    phase 2 small molecule active

    1 trial

  24. sintilimab

    The First People's Hospital of Lianyungang

    Colorectal Neoplasms

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources